The Life Sciences Report Blog | Talkmarkets | Page 1
Experience, Creativity And Dedication To Finding And Presenting The Best Investment Ideas
Contributor's Links: The Life Sciences Report

The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. 

The Streetwise Reports Team combines experience, creativity and ... more


Latest Posts
1 to 16 of 39 Posts
1 2 3
Oil Breaking Out, But The Money Is Elsewhere
One resource industry dwarfs the rest of them put together: energy.
Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Inovio Pharmaceuticals Inc. exited Q2/17 with $92 million in cash. It has closed a public offering that yielded $70.5 million, which "would be used for general corporate purposes, including clinical trial expenses.
HIV Vaccine Clinical Study Results In High Immune Response Rates In Healthy Subjects
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. Inovio Pharmaceuticals Inc. has a "buy" rating.
RXi Pharmaceuticals Receives Japanese Patent For RNAi Platform
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform.
Regeneus Hits The Fast Track With Major Japanese Partnership
Regeneus, an Australian company, has entered into an collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
OncoSec Delivers Cancer Therapy Straight To The Tumor
OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor...
With Potential Vaccines For Cancer, Ebola And Zika, Inovio Could Have An Explosive 2016
Recent news from Inovio Pharmaceuticals Inc., developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika could make the stock explode.
Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain And Opioid Abuse
Relmada's Therapeutics Inc. Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
Diffusion Pharmaceuticals Takes Aim At Brain Cancer: CEO David Kalergis
David Kalergis, CEO of Diffusion Pharmaceutical lays out the plan for pivotal development of treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful.
Moseda Joins Telus And Apple In The $20B Patient Home Monitoring Sector
EO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution. She developed innovative, secure mobile software solutions for the $20 billion community/home care market.
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital
Eden Rahim of Toronto-based Next Edge Capital describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot.
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
CAR T-Cell Therapeutics: Alan Leong Of BioWatch Looks Beyond The Buzz For Solid Early-Stage Plays
Alan Leong, senior analyst with BioWatch, tells us about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies.
Buy Biotech When There's Blood On The Street: Pontifax's Ran Nussbaum
Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life.
Acquisitions Power Growth Of Companies And Portfolios: StoneCastle's Bruce Campbell
Bruce Campbell of StoneCastle Investment Management describes five small-cap growth stories poised to ring up more acquisitions, more cash flow and more share price appreciation to portfolios.
1 to 16 of 39 Posts
1 2 3